As there is no cure for MMBD, our work suggests improving anti-angiogenic drugs and targeting osteocytic Vegf-a and/or Fgf23 could be an effective therapeutic approach for MM patients. This evidence concerns the gene FGF23 and Miyoshi myopathy.